cabozantinib,atezolizumab
roche
['contact03']
#asco23
the much awaited data from #contact03 @ the oral session presented by - ici was given in the immediate preceding line - pfs and os similar in both arms - more saes (24% vs. 11%) with the combo
conclusion: very important to do rcts for effective conclusions 
GU Oncologist/Clinical Trials/ Experimental Therapeutics @UCD_Cancer @UCDavisHealth via @uofcincy @GoBEARCATS. Tweets= My opinions #RCC #ASCO #immunotherapy